Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Christopher Plescia"'
Autor:
Siqing Fu, Rom S Leidner, Ki Chung, Jiaxin Niu, Ilian Tchakov, Debra L Richardson, Xiaoping Qing, Jorge Nieva, Douglas Adkins, Alan L Ho, Minh Phan, Alexander T Pearson, Marshall R Posner, Lisle Nabell, Stuart Wong, Katerin Rojas, Ari J Rosenberg, Trisha Kaufmann, Christopher Plescia, Corinne Iacobucci, Kia Katchar, Klaus Orlinger, Katia Schlienger, David G Pfister
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/2139506c3af64695acf470195ba8dd75
Autor:
Daniel S. Leventhal, Anna Sokolovska, Ning Li, Christopher Plescia, Starsha A. Kolodziej, Carey W. Gallant, Rudy Christmas, Jian-Rong Gao, Michael J. James, Andres Abin-Fuentes, Munira Momin, Christopher Bergeron, Adam Fisher, Paul F. Miller, Kip A. West, Jose M. Lora
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Synthetic biology can be used to create rationally designed living therapeutics. Here the authors engineer E. coli Nissle to target STING activation in antigen presenting cells for the treatment of solid tumors and demonstrate preclinical activity in
Externí odkaz:
https://doaj.org/article/c274837c940442a5b5b9051d086275aa
Autor:
Michael J. Thomenius, Alejandra Raimondi, Scott A. Ribich, Sarah K. Knutson, Elayne Chan-Penebre, Heike Keilhack, Robert A. Copeland, Jesse J. Smith, Christopher Plescia, Igor Feldman, Natalie M. Warholic, Vinny Motwani, Trupti Lingaraj, Allison Drew, Danielle Johnston-Blackwell, Dorothy Brach
The EZH2 small-molecule inhibitor tazemetostat (EPZ-6438) is currently being evaluated in phase II clinical trials for the treatment of non-Hodgkin lymphoma (NHL). We have previously shown that EZH2 inhibitors display an antiproliferative effect in m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16635ec96cb32a617f49970fa6370768
https://doi.org/10.1158/1535-7163.c.6539623.v1
https://doi.org/10.1158/1535-7163.c.6539623.v1
Autor:
Michael J. Thomenius, Alejandra Raimondi, Scott A. Ribich, Sarah K. Knutson, Elayne Chan-Penebre, Heike Keilhack, Robert A. Copeland, Jesse J. Smith, Christopher Plescia, Igor Feldman, Natalie M. Warholic, Vinny Motwani, Trupti Lingaraj, Allison Drew, Danielle Johnston-Blackwell, Dorothy Brach
Table S1: Conditions and seeding densities of all cell lines used in studies; Table S2. Single agent IC50 values for agents tested for 3 days in 96-well plates as described in Materials and Methods; Figure S1. Tazemetostat dosing reduced H3K27me3 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::028053566081cf3c139a50ed258075a7
https://doi.org/10.1158/1535-7163.22510432
https://doi.org/10.1158/1535-7163.22510432
Autor:
Carey W. Gallant, Christopher Plescia, Paul F. Miller, Michael J. James, Kip A. West, Rudy Christmas, Daniel S. Leventhal, Jian-Rong Gao, Ning Li, Adam B. Fisher, Starsha Kolodziej, Munira Momin, Christopher Bergeron, Anna Sokolovska, Andres Abin-Fuentes, Jose M. Lora
Publikováno v:
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Synthetic biology is a powerful tool to create therapeutics which can be rationally designed to enable unique and combinatorial functionalities. Here we utilize non-pathogenic E coli Nissle as a versatile platform for the development of a living biot
Autor:
Sarah K. Knutson, Scott Ribich, Allison Drew, Heike Keilhack, Igor Feldman, J. Joshua Smith, Danielle Johnston-Blackwell, Michael Thomenius, Christopher Plescia, Elayne Chan-Penebre, Trupti Lingaraj, Robert A. Copeland, Vinny Motwani, Alejandra Raimondi, Natalie Warholic, Dorothy Brach
Publikováno v:
Molecular Cancer Therapeutics. 16:2586-2597
The EZH2 small-molecule inhibitor tazemetostat (EPZ-6438) is currently being evaluated in phase II clinical trials for the treatment of non-Hodgkin lymphoma (NHL). We have previously shown that EZH2 inhibitors display an antiproliferative effect in m
Autor:
Christopher Plescia, Karen Campbell, Tiffany Chen, Ramez N. Eskander, Alexander I. Spira, Ezra E.W. Cohen, Johanna C. Bendell, Geoffrey Kuesters, Omid Hamid
Publikováno v:
Journal of Clinical Oncology. 39:TPS2664-TPS2664
TPS2664 Background: High-risk strains of HPV (HPV 16/18) have been associated with the development of multiple cancers, and the associated viral antigens are validated targets from immunotherapy approaches. We engineered red blood cells into allogene
Autor:
Alice McDonald, Stephen J. Blakemore, Sarah K. Knutson, Robert A. Copeland, Heike Keilhack, Natalie Warholic, Jesse Smith, Christopher Plescia
Publikováno v:
Molecular Cancer Therapeutics. 14:B133-B133
Introduction: Evaluating the effects of epigenetic modulators on the methylation state of histones in heterogeneous cell populations has, to this point, been limited to bulk assessment of cell lysates or purified histones. Hence, determining the diff
Autor:
Christopher Plescia, Sarah K. Knutson, Heike Keilhack, Allison Drew, J. Joshua Smith, Scott Ribich, Robert A. Copeland
Publikováno v:
Molecular Cancer Therapeutics. 14:C87-C87
Introduction: The H3K27 histone methyltransferase EZH2 is the catalytic component of the polycomb repressive complex 2 (PRC2), and is amplified, overexpressed, or mutated in multiple cancer types, supporting its function as an oncogene. In addition t
Autor:
Trupti Lingaraj, Alison Drew, Danielle Johnston, Scott Ribich, Alejandra Raimondi, Dorothy Brach, Sarah K. Knutson, Heike Keilhack, Christopher Plescia, Natalie Warholic, Robert A. Copeland, J. Joshua Smith, Elayne Penebre, Michael Thomenius
Publikováno v:
Molecular Cancer Therapeutics. 14:B85-B85
The EZH2 inhibitor tazemetostat (EPZ-6438) is emerging as a promising therapeutic agent for the treatment of non-Hodgkin's Lymphoma (NHL). A significant body of work has now demonstrated in vitro and in vivo effects of EZH2 inhibition in preclinical